Abstract. Although it is often described as ''immunologically privileged,'' the brain can display vigorous immune activity, both clinically and experimentally. The underlying control mechanisms are under active study. Here we shift attention from the brain as a whole to its diverse microenvironments. We review evidence that immune regulation in the brain is site-specific, and that local neurochemicals contribute to the site-specific control. Key points are illustrated by recent work from a rat model in which local injection of the proinflammatory cytokine, IFN-␥, was used to modulate 2 essential aspects of the cell-mediated immune response: T cell entry from the blood, and expression of the MHC proteins that are needed to present antigen to the newly entered T cells. A growing number of neurologic disorders are known to be exacerbated by the immune/inflammatory network. Understanding the factors that influence local immune function may help explain the distribution of localized CNS damage and, more importantly, may suggest new therapeutic approaches for both desirable and unwanted responses.
INTRODUCTION
The central nervous system (CNS) functions through the interplay of microenvironments that are structurally, functionally, and chemically heterogeneous. The neurochemical milieu includes neurotransmitters, neuropeptides, growth factors, and other molecules whose abundance differs between, and even within, neuroanatomic structures. Recent work shows that immune regulation also differs between CNS regions (1) (2) (3) (4) (5) (6) , and suggests that the neurochemical microenvironment is a contributing factor (5, 6) .
Understanding the basis of regional diversity in immune regulation is an important step toward therapeutic control of the immune response in the CNS. Whether the desired outcome is a decrease in immune function (for prevention of graft rejection or autoimmunity) or an increase (for control of tumor or infection), the principles governing local regulation must first be revealed.
Here, we illustrate site-specific immune regulation in the CNS and review evidence for a local neurochemical influence. The necessary interplay between in vitro models and in vivo work is highlighted. Clinical implications of site-specific regulation and of the proposed role of local neurochemicals are suggested.
IMMUNE ''PRIVILEGE'' AND THE CELL-MEDIATED IMMUNE RESPONSE IN THE CNS
Although the brain is often described as an ''immunologically privileged'' site (7) (8) (9) , this term has been misunderstood. Like muscle (10) and many other nonlymphoid tissues, the normal CNS is immunologically quiescent. Few leukocytes or activated antigen-presenting Supported by NINDS grant #NS29510 to L.A.L., and National Multiple Sclerosis Society fellowship #FG1213 and NIH #MH11612 to L.P.M. cells are seen. Expression of the endothelial adhesion molecules that facilitate leukocyte entry and of the major histocompatibility (MHC) proteins that mediate antigenpresentation are both downregulated (11) . However, in the CNS, as in other tissues, immune function is under active regulatory control and vigorous responses can be seen (11) . While immune activity is important for control of tumor and infection (12) , dysregulated or unwanted responses, including uncontrolled inflammation, autoimmunity, and graft rejection are major concerns. Finding the optimal balance between desirable and unwanted responses is currently a major challenge.
Most research in CNS immunology has treated the brain as a whole or made only broad anatomical distinctions, such as white matter vs grey matter, or meninges vs parenchyma. Here, we draw attention to variations in immune regulation between and within discrete anatomical areas, and review evidence that local neurochemicals are involved. The immunological context is control of the T cell-mediated response by the proinflammatory cytokine, gamma interferon (IFN-␥). To set the stage, 2 key aspects of the T cell-mediated response in the brain are reviewed below.
Control of T Cell Entry to the CNS
An immune response is initiated most efficiently in organized lymphoid tissue, such as the lymph nodes or spleen. Once T cells have been stimulated by antigen, they acquire properties that enhance their ability to reach and respond to antigen in nonlymphoid tissues, including the CNS. They are more likely to enter the nonlymphoid tissues, and are more readily triggered by their antigen when they encounter it (11) .
First, the activated T cells must enter the brain through cerebral vessels. T cells circulate at random through the vasculature until they are arrested by adhesive interactions with the vessel (13, 14) . Although the necessary adhesion molecules are downregulated in the normal brain, their expression is under regulatory control. Proinflammatory cytokines, including IFN-␥, are among the signals that up-regulate the expression of these and other relevant molecules (14) (15) (16) (17) (18) (19) . The multi-step activation process involves increased levels of adhesion ligands such as ICAM-1 and VCAM-1 (15) (16) (17) (18) . T cell/endothelial adhesion initiates a chain of events that culminates in T cell extravasation, a metabolically active process that is not blocked by the physical blood-brain barrier (BBB) (11) . The activation state of the T cell and of the vessel are at least additive in their effect on the number of entering T cells (14, 19) .
Although T cell migration patterns are commonly described in terms of whole organs, differences in T cell traffic within different lymphoid microenvironments are well known. Here we draw attention to site-specific differences in the regulation of T cell entry to the CNS, stressing the potential role of the local neurochemical milieu. Such differences are particularly easy to detect against the brain's low T cell background. At a gross level, T cell entry to the brain appears to be governed by the same molecules and mechanisms used for other nonlymphoid tissues. It seems likely that site-specific regulation, with the local regulatory milieu as a contributing factor, will be found in other nonlymphoid tissues as well.
Control of Antigen Presentation
Once an activated T cell has entered the brain, it must recognize that its antigen is present. A basic requirement for recognition by the T cell is that antigen must be processed into peptides, and the peptides complexed with major histocompatibility (MHC) proteins. MHC expression is weak, at best, in most cells of the normal brain, but is upregulated in many different pathological and experimental conditions (20, 21) . One of the most efficient ways to upregulate MHC expression is by exposure to the proinflammatory cytokine, IFN-␥ (5, 22, 23) .
Recognition of the peptide-MHC complex triggers the T cell to perform its effector functions. These may include direct target attack as well as attraction or activation of other cells that in turn attack the target (11) . The end result can include viral clearance or tumor control, but also bystander damage, uncontrolled inflammation, autoimmunity, or graft rejection. Learning how a safe balance is maintained normally, or how it can be achieved therapeutically, are major goals of current research.
IN VITRO EVIDENCE THAT NEUROCHEMICALS CAN INFLUENCE IMMUNE REGULATION

Regulation of T Cell Function
Much of the initial evidence that neurochemicals can influence the T cell mediated response has come from in vitro studies. Lymphocytes have receptors for various neurotransmitters, peptides, and hormones, and are able to form a biological response to them. T cells can also produce many of these same neurochemicals, providing mechanisms for feedback regulation of T cell function and perhaps modulation of neural cell function as well (24) .
Among the most widely studied groups of neurochemicals in terms of neural-immune communication have been the stress hormones. Hypothalamic, pituitary, and adrenal hormones, such as CRF, ACTH, and glucocorticoids, respectively, generally suppress T cell functions. For example, lymphocyte proliferation is typically decreased by glucocorticoids (24) , paralleling the known immunosuppressive properties of these molecules in vivo (25) .
Neuropeptides have been the focus of several experiments in vitro. Substance P (SP) can stimulate T cells to proliferate (26, 27) and to produce the essential T cell growth factor, IL-2 (28) and other cytokines (29) . Other neuropeptides, such as vasoactive intestinal peptide (VIP) and somatostatin suppressed T cell proliferation in some studies (26, 27) . In other studies, VIP and somatostatin stimulated IL-2 production and had no effect on T cell proliferation (28) . The diversity of lymphocyte responses in vitro, where the participating cell types and levels of regulatory molecules are known, illustrates the potential complexity of immune regulation, and the need for in vivo studies to help define the dominant effects.
In vitro studies have shown that neurochemicals are also able to influence T cell/endothelial interactions. Among neuroregulatory molecules that are distributed in specific regional patterns, SP and calcitonin gene-related peptide (CGRP) increase lymphocyte-endothelial cell adhesion (30) (31) (32) and secretoneurin enhances monocyte migration (33) .
In summary, although several neurochemicals have been shown to affect lymphocytes in vitro, the results vary depending on the type of lymphocyte, the dose of neuroregulatory molecule, and the effector function examined (26) . This complexity underlines the need for in vivo models that can reveal the most important activities for further study.
Regulation of MHC Expression
MHC expression is downregulated in most cells of the normal brain. It is readily upregulated pathologically and experimentally, but with a nonuniform distribution. Even after MHC upregulation, class I MHC proteins, the main MHC class used by cells that present their own antigens, are expressed most strongly on endothelial cells. Under most conditions of MHC upregulation, class II MHC proteins, the main MHC class used by antigen-presenting cells (APC) to present ingested antigen, are expressed most strongly on phagocytes. These include blood-borne monocytes, perivascular phagocytes, parenchymal microglia, and tissue macrophages. In most cases, MHC expression on neurons, astrocytes or oligodendrocytes, and many tumor cells remains weak, at best (11, 21).
SITE-SPECIFIC IMMUNE REGULATION IN THE CNS
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In vitro studies reveal a greater potential for MHC expression than is commonly seen in vivo. Astrocytes do not normally show detectable class II MHC expression in vivo, even in pathological or experimental settings where strong expression is detected in adjacent microglia (34, 35) . For example, direct intracerebral injection of 10 4 U IFN-␥ stimulates microglial class II expression throughout the rat brain, while astrocytes (as well as neurons, oligodendrocytes, and most glial brain tumor cells) show no detectable expression (5, 11, 23) . In culture, however, astrocytes do show strong class II expression after exposure to IFN-␥, and may even spontaneously up-regulate class II (35, 36) . Tumor cells can show a similar dichotomy between MHC regulation in vivo and in vitro (37) . MHC regulation can also vary depending on whether different cell types are studied separately or in combination (38) .
The implication of the work described above is that, for some cell types, MHC expression may be actively suppressed in vivo. Provocative work in the hippocampal slice suggests that neuronal activity may have such a suppressive influence. In addition, several neuropeptides and neurotransmitters, including glutamate (39, 40) and norepinephrine (NE; ref 41) have been shown to suppress INF-␥ mediated class II induction in vitro. These in vitro results suggest that MHC induction in vivo may be suppressed in CNS regions with high concentrations of glutamate or NE. We recently found this to be the case for one such region (area CA1 of the hippocampus), as described below (5, 42) .
In a more general sense, the initially conflicting results on MHC modulation illustrate the full interplay that is possible and desirable between in vitro models and in vivo work. The easily triggered class II expression that is seen on astrocytes in vitro but not in vivo does not invalidate the in vitro work. Rather, it provides a clue to the cells' full potential, and stimulates identification of the factors that control it.
Regional Heterogeneity Shown by Isolated Cells In Vitro
Complementing local neurochemical diversity, intrinsic differences in the way cells from different areas respond to immunomodulators have been shown in several studies (43, 44) . Most of this work has utilized neonatal astrocyte cultures, in part because of astrocytes' proposed role in inflammatory demyelination, and in part because of the relative ease of isolating neonatal astrocytes as opposed to other neonatal brain cells or adult cells. These studies have identified several properties of astrocytes that differ according to their CNS region of origin. For example, when added to brainstem astrocytes, the cytokine transforming growth factor-␤ (TGF-␤) enhanced proliferation and also prevented induction of class II MHC proteins. In forebrain astrocytes, in contrast, TGF-␤ had a smaller effect on proliferation and class II induction was not prevented (43) .
Cultured astrocytes also maintain their regional specificity with regard to expression of neuropeptides. Among neuropeptides that are known to affect T cell function, somatostatin mRNA is relatively abundant in cerebellar astrocytes, while proenkephalin mRNA and enkephalin peptides are more abundant in astrocytes from cortex, striatum, and cerebellum (44) .
In summary, astrocytes exhibit site-specific heterogeneity in their response to cytokine, in their MHC regulation and thus their capacity to mediate antigen presentation, and in production of peptides known to affect immune function in other contexts. The site-specific isolation of other CNS cells is likely to provide similar insights, and will be an important complement to studies in vivo.
SITE-SPECIFIC REGULATION OF IMMUNE ACTIVITY IN VIVO Site-specific Cytokine Expression
The presence of cytokines in the brain has received a great deal of attention (45, 46) , and the regional expression of many cytokines and their receptors has been mapped in rodents (2, 47) . Possible routes of cytokine entry to the brain include active transport, passage through a weak blood-brain barrier (BBB) at the circumventricular organs, and leakage through a damaged BBB in disease (45) . At least as important, cytokines can be produced locally by activated T cells, microglia, macroglia, and even neurons (45). Locally released cytokines can then contribute to regulatory cascades with a variety of potential suppressive or activating effects, including further activation of T cells and glia. Thus, regional heterogeneity in T cell entry and glial activation can influence cytokine levels, which can then further amplify the original site-specific effects.
Regulation of T Cell Entry
T cell entry to the brain is influenced by the activation state of the T cell and of the vessel, as summarized above. Building on the evidence reviewed here, we hypothesized that control of T cell entry would vary in different CNS microenvironments. To test this hypothesis, we compared T cell entry to 2 spatially distant sites that also have very different neurochemical environments: the hippocampus and the brainstem (6) .
Although many of the same neuroregulatory molecules are utilized in the hippocampus and brainstem, the proportions and combinations diverge. Prominent neurochemicals in the brainstem include peptides such as SP and VIP, which can affect T cell function in opposite ways in vitro. While these same peptides are present in the hippocampus, the excitatory neurotransmitter, glutamate, is particularly abundant and functionally important and has a downregulatory effect on immune function in other contexts (39, 40) . There are also local differences in other molecules that influence immune activity, including growth factors, cytokines, and adhesion molecules (2, 45, 47) . The complexity of the microenvironment mandated in vivo studies to determine the net effect on T cell entry.
Because few T cells spontaneously enter the normal brain, we provided dual signals to stimulate entry so that local differences could be compared (6) . First, a population of activated T cells was created by immunizing rats with the normal CNS protein, myelin basic protein (MBP).
Subsequently, vessels were activated by microinjecting the proinflammatory cytokine, IFN-␥, into area CA1 of the hippocampus and into the nucleus of the solitary tract (NTS) in the brainstem of the same rats. Consistent with our hypothesis, these 2 regions showed both qualitative and quantitative differences in the patterns of T cell entry.
After local IFN-␥ injection, T cells that entered the hippocampus were mainly confined to perivascular cuffs in the hippocampal fissure, with few entering the surrounding parenchyma (Fig. 1A, B) . Andersson and colleagues (48) also found that injection of cytokines (IL-1, IL-8, or TNF-␣) to the hippocampus caused leukocyte cuffing in the hippocampal fissure with little infiltration of the parenchyma. Their studies had used unimmunized rats, leaving open the possibility that activated T cells might migrate differently. In our studies of MBP-primed rats, we found that even when T cells had been activated, few entered the hippocampal parenchyma.
After IFN-␥ injection to the brainstem, not only were cuffed vessels more widely distributed than in the hippocampus, but more T cells entered the parenchyma proper (Fig. 1C) . Counts of stained T cells (in the same sized area/ site) confirmed that significantly more T cells entered brainstem than hippocampus (Fig. 2) . For both hippocampus and brainstem, the majority of T cells around vessels were CD8 ϩ /MHC class I-restricted, while CD4 ϩ /class II-restricted T cells predominated in the parenchyma. Thus heterogeneity of T cell migration was seen in comparisons between 2 anatomic structures (T cell numbers in brainstem vs hippocampus) and also within a given structure (CD4/CD8 ratios in perivascular space vs parenchyma).
Physical factors could not fully explain the greater efficiency of T cell entry to the brainstem. The density of vessels is similar between the 2 sites (49, 50), as are vessel volume, area, and length (50) . The path taken by the injected drug may have contributed, but cannot be the only factor. As we confirmed using a marker protein, protein injected into the brainstem diffuses over a wide area, whereas protein injected into the hippocampus is concentrated in the hippocampal fissure (6) . While these flow patterns may help explain the patterns of cuffed vessels in brainstem vs hippocampus, they do not explain the differences in T cell entry to the brain parenchyma at the 2 sites.
The greater abundance of myelin in the brainstem is also not likely to explain our findings. The early stage of T cell entry to nonlymphoid organs is thought to be dependent on the activation state of the T cell, but independent of the particular antigen (19, (51) (52) (53) . Consistent with this principle, parenchymal T cells were seen in the grey matter of the brainstem as well as the white matter.
An alternative explanation for local differences in T cell entry is that the vessels may be intrinsically different in their response to injected IFN-␥. This could include differences in the density or structure of endothelial receptors for IFN-␥, or differences in the extent to which the endothelial cells increase expression of appropriate adhesion molecules, such as ICAM-1 or VCAM-1, in response to the drug. Direct immunocytochemical analysis of cytokine receptors and adhesion molecules in the different regions will be informative.
We propose that, in addition to any or all of the factors outlined above, the local neuroregulatory environment also influences T cell entry in response to IFN-␥. A number of the neurochemicals found in these areas can affect T cells and T cell/endothelial cell interactions in vitro, as described above. The effect of local neurochemicals on endothelial activation, on T cell passage from perivascular cuffs to the parenchyma proper, and other aspects of T cell migration should be a fruitful area for further analysis.
Local Differences in MHC Modulation
After T cell entry from the blood, a second major control point in the cell-mediated response is the expression of the MHC proteins that mediate antigen presentation. In a complementary set of studies to those described above (6) , graded doses of IFN-␥ were delivered stereotaxically to the rat hippocampus (area CA1) and brainstem (NTS), and local class II MHC expression was compared (5). We focused on class II regulation because presentation of ingested antigen by APC, which is primarily mediated by class II MHC proteins, may be particularly important for brain tumor and other antigens in the CNS (11, 54) .
As shown in Figure 3A and B, upregulation of class II MHC expression was more efficient in brainstem than hippocampus by several measures. More cells showed strong class II expression in the brainstem, and there was generally more staining per cell. Staining of adjacent sections with the monoclonal antibody, OX42, confirmed that most parenchymal class II ϩ cells were microglia, as had been suggested by their characteristic dendritic morphology. No class II ϩ oligodendroglia, astrocytes, neurons, or endothelial cells were observed, consistent with previous work (21, 22) . Computer-assisted image analysis was used to obtain a quantitative measure of the site-specific class II expression. Because microglia have many spindly processes, we computed the proportion of a standard field that was class IIpositive (stained pixels per standard area) rather than counting cell bodies. As shown in Figure 3C and D, both area CA1 and the brainstem showed a dose-dependent increase in class II expression after IFN-␥ injection. However, upregulation of class II was more sensitive to IFN-␥ in the brainstem. Specifically, class II expression increased in response to lower doses of IFN-␥, and reached a higher plateau in the brainstem than in CA1. The brainstem response to IFN-␥ was widespread. As compared with rats injected with buffer alone, local injection of Ն30 U IFN-␥ increased class II expression through the entire rostral-caudal extent of the brainstem. Class II levels in the hippocampus were more variable. While class II expression remained low in the injected CA1 area of the hippocampus, more class II ϩ microglia were seen in the adjacent dentate gyrus, although the numbers varied from rat to rat (5).
The observed differences in class II levels between CA1 and brainstem could not be ascribed to differences in the baseline number of microglia at the 2 sites. The density of microglia in CA1 is at least as great as in the region around the brainstem injection site in the normal rat (Fig. 4) and mouse (55) . Nor could the differences be explained by the patterns of drug dispersal after injection (5). More likely factors were intrinsic differences between the microglia and differences in the local regulatory environment. Intrinsic differences in the response of endogenous brain cells to immunoregulators have already been shown in other contexts (43), as described above. Recent direct evidence for a local neurochemical influence is summarized below.
Outside of the injected regions, qualitative assessment of class II levels was made for other structures. Here too, heterogeneity was observed that was independent of the distance from the injection site and could not be ascribed to the delivery path of the injected drug. For example, few class II ϩ cells were seen in the caudate-putamen of IFN-injected rats, while intermediate numbers were seen in the cortex (Fig. 5) , which was at a comparable distance from the CA1 injection site. Areas among the most efficient at upregulating class II (outside the injected regions) were the corpus callosum (Fig. 5) , white matter layers of the cerebellum, and the thalamus (5).
Other investigators have also found local variations in MHC expression, with the particular pattern dependent on the stimulating signal. In fact, the opposite hierarchy to that observed in our studies (where we found class II MHC in CA1 Ͻ dentate after local injection of IFN-␥) is found in other contexts, including Alzheimer Disease in the human (56) and ischemia in the rat (57) . The important point is that MHC regulation differs at different sites, with the relative MHC levels dependent upon the activating conditions.
Although we stress differences in immune regulation that do not simply reflect the local concentration of the injected drug, route-dependent effects are also of clinical relevance. Different patterns of MHC modulation seen after intracerebral, intrathecal, or intraventricular administration of IFN-␥ can be ascribed, at least in part, to the different relative drug concentrations at different sites (4, 22) . Similarly, preferential flow of drug through white matter vs grey matter can help explain the greater class II enhancement in white matter microglia that is seen after direct IFN-␥ injection to the cerebellum (5) .
An additional factor of clinical relevance is accessibility to blood-borne regulators. The BBB is compromised within a tumor mass and at other sites of damage, and in the circumventricular organs (CVO). Increased MHC expression can indeed be seen at tumor sites (11) , in damaged CNS tissue (20) , and in the CVO (58) . However, the mechanisms underlying the increased MHC expression are not yet known. Besides exposure to blood-borne MHC-enhancing cytokines, other possibilities include entry of MHC ϩ leukocytes (23), adsorption of MHC protein from serum (21) , or, at sites of damage, MHC upregulation in direct response to the damage per se.
We suggest that the local neurochemical milieu is also an important factor in MHC regulation. As described above, many of the same neuroregulatory molecules that have been shown to affect immune function in vitro are found in varying combinations in hippocampus and brainstem. A model of local neurochemical influence over immune activity leads to the prediction that manipulating important neurochemicals in each environment may also affect immune regulation. We have recently found that selective manipulation of the local environment leads to just such an outcome, as described below.
Neurochemicals Can Affect MHC Regulation In Vivo
One of the most widely studied neurochemicals, in terms of immune regulation, is SP. This peptide displays a variety of immune-stimulating activities in vitro (above). In vivo, outside the brain, SP influences T cell migration (59) and mediates neurogenic inflammation (60) . Taking into account the regional distribution of SP in the CNS, with greater abundance in brainstem than hippocampus (61), we asked if microglial class II upregulation in response to IFN-␥ might be affected by SP.
To examine SP effects on class II modulation, stereotaxic injections of 300 U IFN-␥ were made into the hippocampus or brainstem, using the same model described above (5, 6) . Immediately following the IFN-␥ injection, graded doses of SP (0.01-100 ng), or of the SP receptor (NK-1) antagonist, Spantide I, were delivered to the same site (42) . As shown in Figure 6 , there were dramatic differences in microglial class II levels in the brainstem after SP manipulation. Even compared with the elevated class II levels elicited by IFN-␥ alone (Fig. 6A) , there was a further increase in class II when 1 ng of SP was also administered (Fig. 6B) . In contrast, rats that received 10 ng of Spantide I after IFN-␥ did not show increased class II expression above background levels (42) . Provocatively, even though SP did influence class II modulation in the brainstem, doses ranging from 10 Ϫ7 to 50 mg failed to enhance the ability of IFN-␥ to increase class II expression by microglia in the hippocampus.
In summary, both the microglial response to IFN-␥ and the ability of SP to enhance that response are site-specific. Differences in MHC expression between brainstem and hippocampus parallel the concentration of SP and its receptors in these areas (CA1 K NTS; refs. 61, 62), suggesting that manipulation of more prominent components of the hippocampal microenvironment may be more effective in CA1. Indeed, preliminary data suggests that the excitatory neurotransmitter, glutamate, suppresses IFNmediated MHC induction in vivo (42) , consistent with earlier work in vitro (39, 40) .
Clinical Implications of Local Immune Regulation
The immune/inflammatory network is implicated, at least as an exacerbating factor, in an increasing number of neurologic disorders (11), including Alzheimer Disease (63), AIDS dementia complex (12, 64) , and stroke (65) . Attention to the potential role of local neurochemicals in immune regulation should increase our understanding of these disorders. First, the distribution and combination of neurochemicals with the ability to regulate immune activity may influence the anatomical pattern of some disorders. For example, we have found that T cell entry and the potential for MHC-restricted antigen presentation are greater in the brainstem than hippocampus. A parallel distribution is seen in MS, where plaques are common in the brainstem and rare in the hippocampus (66, 67) , and in an animal model of CNS autoimmunity, experimental allergic encephalomyelitis (EAE) (1) . Whether local neurochemicals contribute to greater brainstem involvement, as is suggested by our studies (42) , must now be defined.
An additional implication of site-specific immune activity is that new strategies for immune control are suggested, with the particular manipulation dependent upon on the change desired. For example, manipulating the local neurochemical environment in the brainstem may enhance immune activity against brainstem glioma (11), while altering it in a reciprocal way may contribute to reducing brainstem damage in MS. 
SUMMARY AND CONCLUSIONS
That neurotransmitters, neuropeptides, and other neurochemicals can affect immune parameters in vitro is well documented. Within the brain, differences in the local combinations and amounts of such neurochemicals suggest that immune function may also vary between microenvironments. In support of this hypothesis, we have demonstrated site-specific regulation of 2 key aspects of the cellmediated immune response: entry of activated T cells (6) and modulation of the MHC proteins that are required for antigen presentation to them (5) . In each case, the brainstem is more sensitive than the hippocampus to the immune-enhancing effects of IFN-␥, and evidence for sitespecific immune regulation in other brain regions was also found. Most recently, direct evidence that local neurochemicals such as SP and glutamate contribute to this sitespecific immune regulation was obtained (42) .
The Next Steps
Further understanding of local immune regulation will require new concepts as well as new methods. The complexity of the neurochemical environment mandates in vivo analysis to determine the net effect of neurochemicals that may have opposing effects in vitro. Conversely, in vitro studies can reveal potential activities that are normally prevented or suppressed in vivo. Choosing or adapting experimental models to facilitate translation of new findings to human patients is a major current challenge.
New ways of thinking about regulatory complexity are also needed. The multi-functional nature of biological molecules is increasingly appreciated (68) . SP, for example, affects not only pain and other neural functions, but also a variety of immune functions. How are specific effects achieved normally? How can a desired effect be achieved therapeutically? Multiple activities of a single regulatory molecule may be separated by anatomical boundaries, follow different kinetics, or display different dose-response curves. They may be mediated through different receptor subtypes or second messengers, and may be affected differently by other components of the local regulatory milieu. Having enumerated these possibilities, the challenge of finding new ways to understand and modulate the full complexity of neural/immune interactions remains.
